Evogene, DuPont Expand Deal Aimed at Soybean Disease Resistance | GenomeWeb

NEW YORK (GenomeWeb News) – Evogene today announced that it and DuPont Pioneer have extended and expanded their multiyear research collaboration aimed at developing varieties of soybean resistant to Asian Soybean Rust, or ASR.

As part of the expanded deal, novel genes identified by Evogene will be evaluated and validated by DuPont Pioneer, the seed business of DuPont, as possible candidates for further development and commercialization. Evogene's Gene2Product computational platform will be added to the gene discovery program, as well.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.